NVS is a partner of GERN's, but they are one of many on the telomerase program, and I do not believe that this partnership is significant financially to either party yet. Remember this vaccine program is still in an EXTREMELY early stage, there is no evidence that this therapy works in human subjects yet, contrary to the interpretation by the newswires today. A Phase 1 study is currently underway, so we are a long way from any evidence that this actually works. Most cancer vaccine programs have failed in later stages of development (Phase 2 or 3) with the exception of CEGE's GVAX program which is well into Phase 3 and I think it has a decent shot at being fileable. But only time will tell on that. Back to GERN: I would use today's rally to short it with both hands if I could get any stock, given the past history of cancer vaccine development and the infant stage of GERN's program.